Articles by tag: breast-cancer

Vepdegestrant: FDA approved the first PROTAC degrader

FDA approved Vepdegestrant — the first protein degrader tablet for ESR1-mutant breast cancer. PFS 5 months vs 2.1 for fulvestrant. Learn why this is a paradigm shift.

Gedatolisib: Phase 3 success in PIK3CA-mutated cancer

Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.

Vepdegestrant: the first breast cancer protein degrader

FDA approved vepdegestrant — the first PROTAC degrader for breast cancer with ESR1 mutation. Learn how it destroys resistance and what will change in therapy. Details here.